US7140461093
© BusinessWire
16.12.2025
RVTY
LISTED
NYSE
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
News Preview
Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in‑silico generation, predictive modeling, and experimen...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
RVTY
LISTED
NYSE
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
News Preview
Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solu...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
RVTY
LISTED
NYSE
Revvity to Present at Upcoming Investor Conferences
News Preview
Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:
UBS Global Healthcare Conference 2025
Monday, November 10, 2025
8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
Jefferies 2025 London Healthcare Conference
Tuesday, November 18, 2025
2:00 p.m. GMT – Max Krakowiak...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
27.10.2025
RVTY
LISTED
NYSE
Revvity Announces Financial Results for the Third Quarter of 2025
News Preview
Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.
The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from con...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
23.10.2025
RVTY
LISTED
NYSE
Revvity Board Declares Quarterly Dividend
News Preview
The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to acti...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
RVTY
LISTED
NYSE
Revvity Showcases Progress with Purpose in 2025 Impact Report
News Preview
Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company’s sustainability, social and governance strategy, initiatives and performance. This year’s report, Progress with Purpose: Science and Sustainability, highlights the Company’s strengthened partnerships, product innovation, sustainability dr...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
RVTY
LISTED
NYSE
Revvity to Hold Earnings Call on Monday, October 27, 2025
News Preview
Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer,...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
RVTY
LISTED
NYSE
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
News Preview
Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN and NASDAQ: SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.
T1D is...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
RVTY
LISTED
NYSE
Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis
News Preview
Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
RVTY
LISTED
NYSE
Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems
News Preview
Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.
This new Pin-point configuration allows for inc...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
RVTY
LISTED
NYSE
Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina
News Preview
Revvity, Inc. (NYSE: RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state’s Research Triangle. The center consolidates Revvity’s expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and o...
Themefolio
Profiler
Peergroup
© BusinessWire
18.08.2025
RVTY
LISTED
NYSE
Revvity to Present at Upcoming Investor Conferences
News Preview
Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:
2025 Wells Fargo Healthcare Conference
Wednesday, September 3, 2025
8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
2025 Baird Global Healthcare Conference
Tuesday, September 9, 2025
2:35 p.m. ET – Steve Willoughby...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
28.07.2025
RVTY
LISTED
NYSE
Revvity Announces Financial Results for the Second Quarter of 2025
News Preview
Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 29, 2025.
The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continu...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
RVTY
LISTED
NYSE
Revvity Board Declares Quarterly Dividend
News Preview
The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action....
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
RVTY
LISTED
NYSE
Revvity to Hold Earnings Call on Monday, July 28, 2025
News Preview
Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, wi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
RVTY
LISTED
NYSE
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
News Preview
Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
RVTY
LISTED
NYSE
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
News Preview
Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument wit...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
RVTY
LISTED
NYSE
Revvity to Present at Upcoming Investor Conferences
News Preview
Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:
Bank of America Global Healthcare Conference 2025
Tuesday, May 13, 2025
9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer
Goldman Sachs 46th Annual Global Healthcare Conference
Tuesday, June 10, 2025
8:00 a.m. ET - Pra...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
RVTY
LISTED
NYSE
Revvity Announces Financial Results for the First Quarter of 2025
News Preview
Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025.
The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continui...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
RVTY
LISTED
NYSE
Revvity Board Declares Quarterly Dividend
News Preview
The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
RVTY
LISTED
NYSE
Revvity to Hold Earnings Call on Monday, April 28, 2025
News Preview
Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, wi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
RVTY
LISTED
NYSE
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
News Preview
Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
RVTY
LISTED
NYSE
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
News Preview
Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions. This expanded relationship builds upon the previously disclosed agreement to perform DNA ext...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
RVTY
LISTED
NYSE
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
News Preview
Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serologi...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
RVTY
LISTED
NYSE
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
News Preview
Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity’s rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software.
This ruling follows a preliminary injunction issued in April 2024, which will become perm...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
RVTY
LISTED
NYSE
Revvity to Present at Upcoming Investor Conferences
News Preview
Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025:
46th Annual Raymond James Institutional Investor Conference
Monday, March 3, 2025
7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
TD Cowen 45th Annual Health Care Conference
Tuesday, March 4, 2025
9:10...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
RVTY
LISTED
NYSE
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
News Preview
Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024.
Fourth Quarter 2024
The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
RVTY
LISTED
NYSE
Revvity Board Declares Quarterly Dividend
News Preview
The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 9, 2025 to all shareholders of record at the close of business on April 18, 2025.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
RVTY
LISTED
NYSE
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
News Preview
Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introdu...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2025
RVTY
LISTED
NYSE
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
News Preview
Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief fina...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
RVTY
LISTED
NYSE
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
News Preview
Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testoster...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
RVTY
LISTED
NYSE
Revvity to Present at J.P. Morgan Healthcare Conference
News Preview
Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA.
President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities.
To access the presentation, a live audio webcast will be available...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
RVTY
LISTED
NYSE
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
News Preview
Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
RVTY
LISTED
NYSE
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
News Preview
Revvity, Inc. (NYSE: RVTY), will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL.
Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here.
A live audio webcast will be availabl...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
RVTY
LISTED
NYSE
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
News Preview
Scale Biosciences (Scale BioTM), a leader in innovative and scalable single cell analysis solutions, and Revvity’s (NYSE: RVTY) BioLegend business, a leading provider of world-class biological reagents and tools, today announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
RVTY
LISTED
NYSE
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
News Preview
Revvity, Inc. (NYSE: RVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by members of Revvity’s senior management team on the Company’s key business initiatives, operational achievements and future financial outlook.
The Company also announced strategic adjustments...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
RVTY
LISTED
NYSE
Revvity Announces Financial Results for the Third Quarter of 2024
News Preview
Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024.
The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
RVTY
LISTED
NYSE
Revvity Board Declares Quarterly Dividend
News Preview
The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to acti...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
RVTY
LISTED
NYSE
Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
News Preview
Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This cutting-edge solution is now available to clinical laboratories, aiming to streamline workflows and reduce manual data ent...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
RVTY
LISTED
NYSE
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report
News Preview
Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company’s sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity’s continued evolution and strengthened commitments to creating a lasting, positive impact on the world.
“Whether it’s from developing groundbrea...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2024
RVTY
LISTED
NYSE
Revvity To Hold Earnings Call on Monday, November 4, 2024
News Preview
Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer,...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
RVTY
LISTED
NYSE
Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene
News Preview
Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
RVTY
LISTED
NYSE
Revvity to Present at Upcoming Investor Conferences
News Preview
Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in September 2024:
2024 Wells Fargo Healthcare Conference – Boston, MA
Wednesday, September 4, 2024
8:45 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
2024 Baird Global Healthcare Conference – New York City, NY
Tuesday...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
